Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Questcor Pharmaceuticals ( QCOR) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.6%. By the end of trading, Questcor Pharmaceuticals rose $1.53 (3.3%) to $47.46 on light volume. Throughout the day, 1,384,535 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2,062,400 shares. The stock ranged in a price between $46.03-$47.57 after having opened the day at $46.17 as compared to the previous trading day's close of $45.93. Other companies within the Drugs industry that increased today were: MediciNova ( MNOV), up 31.1%, Intercept Pharmaceuticals ( ICPT), up 16.4%, Oxygen Biotherapeutics ( OXBT), up 15.2% and Senesco Technologies ( SNTI), up 12.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $2.7 billion and is part of the health care sector. The company has a P/E ratio of 14.1, below the S&P 500 P/E ratio of 17.7. Shares are up 71.9% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Vanda Pharmaceuticals ( VNDA), down 22.1%, Aoxing Pharmaceutical Company ( AXN), down 10.0%, Biodel ( BIOD), down 8.6% and Idera Pharmaceuticals ( IDRA), down 8.1% , were all laggards within the drugs industry with Johnson & Johnson ( JNJ) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.